These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 28314308)
1. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma. Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis. Gao R; Wang F; Wang Z; Wu Y; Xu L; Qin Y; Shi H; Tong Z Medicine (Baltimore); 2019 Apr; 98(14):e14979. PubMed ID: 30946324 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166 [TBL] [Abstract][Full Text] [Related]
4. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma. Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930 [TBL] [Abstract][Full Text] [Related]
5. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982 [TBL] [Abstract][Full Text] [Related]
6. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Kirschner MB; Pulford E; Hoda MA; Rozsas A; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; László V; Klikovits T; Vallely MP; Grusch M; Hegedus B; Dome B; Klepetko W; van Zandwijk N; Klebe S; Reid G Br J Cancer; 2015 Sep; 113(6):963-9. PubMed ID: 26263483 [TBL] [Abstract][Full Text] [Related]
7. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA. Filiberti R; Parodi S; Libener R; Ivaldi GP; Canessa PA; Ugolini D; Bobbio B; Marroni P Med Oncol; 2013 Jun; 30(2):543. PubMed ID: 23532816 [TBL] [Abstract][Full Text] [Related]
9. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology. Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183 [TBL] [Abstract][Full Text] [Related]
10. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma. Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636 [TBL] [Abstract][Full Text] [Related]
11. Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report. Canessa PA; Ferro P; Manta C; Sivori M; Franceschini MC; Fedeli F; Roncella S Med Oncol; 2013; 30(3):649. PubMed ID: 23873013 [TBL] [Abstract][Full Text] [Related]
12. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037 [TBL] [Abstract][Full Text] [Related]
13. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center. Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445 [TBL] [Abstract][Full Text] [Related]
14. Biomarkers for malignant pleural mesothelioma: a meta-analysis. Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568 [TBL] [Abstract][Full Text] [Related]
16. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial. Katz SI; Roshkovan L; Berger I; Friedberg JS; Alley EW; Simone CB; Haas AR; Cengel KA; Sterman DH; Albelda SM Lung Cancer; 2021 Apr; 154():5-12. PubMed ID: 33561782 [TBL] [Abstract][Full Text] [Related]
17. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma. Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420 [TBL] [Abstract][Full Text] [Related]
18. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure. Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653 [TBL] [Abstract][Full Text] [Related]
20. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]